EHMT2 Inhibitor Combination Therapy for Immune Diseases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with overexpression of EHMT2, such as immune-mediated disorders, are often ineffective when used alone, highlighting the need for combination therapies that include EHMT2 inhibitors and other therapeutic agents to achieve superior clinical outcomes.
Innovation Solution
Administering an EHMT2 inhibitor in combination with one or more additional therapeutic agents to treat diseases influenced by the methylation status of non-histone proteins, specifically targeting immune-mediated diseases by modulating T cell activity and reducing pathogenic T cell responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EHMT2 inhibitor is used alone to treat immune-mediated diseases, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent combines EHMT2 inhibitors with additional therapeutic agents to create combination therapies. This merging of treatment modalities addresses the insufficient effectiveness of single-agent therapy while managing the increased complexity through structured combination approaches, thereby resolving the contradiction between therapeutic effectiveness and treatment simplicity.
2Reliability
If combination therapy with EHMT2 inhibitor and additional agents is used, then therapeutic effectiveness is improved, but treatment complexity increases
Solution Approach 1:
The patent systematically combines EHMT2 inhibitors with additional therapeutic agents to achieve superior clinical outcomes. This merging strategy directly addresses the contradiction by accepting increased treatment complexity in exchange for significantly improved therapeutic effectiveness and disease progression inhibition.
3Duration of action of moving object
If single-agent therapy is used, then treatment simplicity is maintained, but disease progression inhibition is insufficient
Solution Approach 1:
The patent employs combination therapies that merge EHMT2 inhibitors with additional agents to extend symptom-free and progression-free time windows. This merging approach resolves the contradiction by sacrificing treatment simplicity to achieve substantially prolonged disease remission periods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively alleviates symptoms, inhibits disease progression, and increases symptom-free or progression-free time windows, providing a more effective treatment approach for immune-mediated diseases compared to using EHMT2 inhibitors or other treatments alone.
Implementation Method 1
Methylation of protein lysine residues is an important signaling mechanism in eukaryotic cells, and the methylation state of histone lysines encodes signals that are recognized by a multitude of proteins and protein complexes in the context of epigenetic gene regulation.
Data Source
AI summary
The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.